The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
The U.S. Food and Drug Administration (FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with treatment ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review ... a novel mechanism for treatment-resistant depression.
Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...